Trial · NCT01720173
Results by group15
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 15 of 15
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free for at Least 6 Months Without Non-protocol Therapy From Study Entry | Dalantercept | 20 | 90% Confidence Interval 11 to 100 | percentage of participants | |
| Incidence of Adverse Effects as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 | Dalantercept | Neutropenia | 1 | Participants | |
| Incidence of Adverse Effects as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 | Dalantercept | Other Investigations | 1 | Participants | |
| Incidence of Adverse Effects as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 | Dalantercept | Cardiac disorders | 3 | Participants | |
| Incidence of Adverse Effects as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 | Dalantercept | Gastrointestinal disorders | 2 | Participants | |
| Incidence of Adverse Effects as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 | Dalantercept | General disorders and administration site conditio | 2 | Participants | |
| Incidence of Adverse Effects as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 | Dalantercept | Infections and infestations | 3 | Participants | |
| Incidence of Adverse Effects as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 | Dalantercept | Metabolism and nutrition disorders | 1 | Participants | |
| Incidence of Adverse Effects as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 | Dalantercept | Musculoskeletal and connective tissue disorders | 1 | Participants | |
| Incidence of Adverse Effects as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 | Dalantercept | Renal and urinary disorders | 1 | Participants | |
| Incidence of Adverse Effects as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 | Dalantercept | Reproductive system and breast disorders | 1 | Participants | |
| Incidence of Adverse Effects as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 | Dalantercept | Respiratory, thoracic and mediastinal disorders | 1 | Participants | |
| Objective Tumor Response | Dalantercept | 0 | 90% Confidence Interval 0 to 100 | percentage of participants | |
| Overall Survival | Dalantercept | 19.8 | 95% Confidence Interval 8.8 to 24.4 | months | |
| Progression-free Survival | Dalantercept | 1.7 | 95% Confidence Interval 1.3 to 3.7 | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01720173/results